MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

CureVac NV

Gesloten

5.39

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.39

Max

5.4

Belangrijke statistieken

By Trading Economics

Inkomsten

-8.3M

-60M

Verkoop

352K

1.2M

K/W

Sectorgemiddelde

5.297

35.739

Winstmarge

-4,816.546

Werknemers

825

EBITDA

-8.2M

-55M

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-18M

1.2B

Vorige openingsprijs

5.39

Vorige sluitingsprijs

5.39

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

CureVac NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jun 2025, 14:20 UTC

Acquisities, Fusies, Overnames

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 jun 2025, 13:34 UTC

Populaire aandelen

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Peer Vergelijking

Prijswijziging

CureVac NV Prognose

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

0

Buy

1

Hold

0

Sell

Technische score

By Trading Central

3.47 / 3.755Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
help-icon Live chat